The net loss of Medscan Group according to IFRS for 2025 amounted to 3.3 billion rubles against a loss of 1.3 billion rubles a year earlier. This is stated in the company's report.
The subsidiaries of Hadassah Medical Ltd and Neot Hashava are included in these consolidated financial statements because the group's management believes that it has control in the absence of direct equity participation in accordance with the cooperation agreements concluded between the group and Hadassah Medical Ltd and Neot Hashava Ltd, respectively.
Revenue increased by 16% to 32.6 billion rubles from 28 billion rubles, gross profit — by 21% to 13.2 billion rubles from 10.9 billion rubles, EBITDA — by 28% to 5 billion rubles from 3.9 billion rubles.
As of December 31, 2025, the group's current liabilities exceeded the group's current assets by RUB 5.68 billion. The report says that the company is in the process of agreeing a deal with a strategic investor to sell a non-controlling interest in a subsidiary in the amount of at least 4.9 billion rubles. The group's management plans to repay its short-term obligations on time, among other things, using the funds received. Also in May 2026, the group plans to issue three-year bonds totaling up to 3 billion rubles.
In 2025, the company issued 17.27 million type A preferred shares with a nominal value of 0.2 rubles, of which 16.97 million shares were purchased by one legal entity at a price of 296.87 rubles. The amount of funds in the amount of 5.04 billion rubles received during the placement is reflected in the capital as part of the prepayment for the additional issue of shares. The report on the results of the issue of type A preferred shares was registered on April 1, 2026.
In 2025, the group gained control of Medica 1 LLC, with a 40% stake. The Group recognized goodwill in the amount of RUB 10,691 million as a result of exceeding the transferred consideration in the amount of RUB 4 thousand. over the share of the acquired negative net assets in the amount of 10.687 million rubles. In February 2026, the group increased its stake in Medica 1 LLC to 49%.
Medscan Group is one of the leaders of the non-governmental healthcare sector in the Russian Federation and offers a full range of high-tech medical care, the company's report says.
The main activities of the group are: diagnostics, outpatient care for adults and children, planned and emergency surgery, rehabilitation, treatment of oncological diseases, as well as the provision of medical laboratories.
The average number of employees of the group during 2025 was 5,724 thousand people, and during 2024 — 5,896 thousand people.
The short—term remuneration accrued to key management personnel in 2025 amounted to 156.663 million rubles, in 2024 - 123.353 million rubles.
In May 2023, a new participant, Sberbank Investments LLC, entered the authorized capital of the subsidiary Medscan Lab LLC and contributed 2.75 billion rubles for a 39% stake. At the same time, the company and the new participant entered into a number of option agreements, according to which the company has the right to buy out this share, and the new participant has the right to sell upon the occurrence of certain conditions. In 2025, the company exercised the specified call option and bought out a 39% stake in the subsidiary's capital.
As of December 31, 2025, the company's direct parent company is JSC Atomic Energy Industrial Complex (as of December 31, 2024 — JSC Rosatom Technologies of Health). The ultimate parent company of the company is Rosatom State Corporation, and its ultimate controlling party is the Russian Federation.
